SCHEMBL239691

SCHEMBL239691

c1ccc(Nn2cnc3ccccc32)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.48
HSD17B10 Q99714 2/20 0.48
ALOX15 P16050 1/20 0.48
TDP1 Q9NUW8 1/20 0.46
CYP11B1 P15538 2/20 0.44
CYP11B2 P19099 2/20 0.44
TNF P01375 1/20 0.44
CYP1A2 P05177 2/20 0.43
CYP2C19 P33261 2/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
CYP2C9 P11712 1/20 0.43
ATM Q13315 1/20 0.43
MEN1 O00255 1/20 0.42
HPGD P15428 1/20 0.42
KMT2A Q03164 1/20 0.42
POLB P06746 1/20 0.41
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
EGLN3 Q9H6Z9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7684323 0.86 CYP1A2 (0.52) HTTHSD17B10ALOX15TDP1CYP11B1
SCHEMBL15022038 0.79 TDP1 (0.52) HTTHSD17B10ALOX15TDP1CYP11B1
SCHEMBL1800353 0.76 TDP1 (0.48) HTTHSD17B10ALOX15TDP1CYP11B1
SCHEMBL1488096 0.76 TDP1 (0.48) HTTHSD17B10ALOX15TDP1CYP11B1
SCHEMBL8573937 0.75 TDP1 (0.41) HTTHSD17B10ALOX15TDP1CYP11B1
SCHEMBL30553026 0.75 SMN1; SMN2 (0.53) HTTHSD17B10CYP1A2ALDH1A1MAPT
SCHEMBL4384670 0.74 HSD17B10 (0.56) HTTHSD17B10ALOX15TDP1CYP11B1
SCHEMBL204727 0.74 ALOX15 (0.64) HTTHSD17B10ALOX15CYP1A2CYP2C19
SCHEMBL9635435 0.74 HSD17B10 (0.49) HSD17B10ALOX15CYP1A2CYP2C19ALDH1A1
SCHEMBL3044318 0.74 HTT (0.46) HTTHSD17B10ALOX15TDP1CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 526 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076072-B2 Nucleic acid labeling compounds AFFYMETRIX, INC. (US) 2011-12-13 US claimed
US-8026057-B2 Nucleic acid labeling compounds AFFYMETRIX, INC. (US) 2011-09-27 US claimed
US-7468243-B2 Nucleotide sequence labelling compoumd four use as tool in genetic engineering AFFYMETRIX, INC. (US) 2008-12-23 US claimed
US-7291463-B2 Incubating/condensating pseudoisocytidine molecule with (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to provide a pseudouridine molecule; oncology diagnosis AFFYMETRIX, INC. (US) 2007-11-06 US claimed
US-7282327-B2 Nucleic acid labeling compounds AFFYMETRIX, INC. (US) 2007-10-16 US claimed
US-4662905-A REACTION PRODUCT OF COPPER SALT AND AN IMIDAZOLE, PYRAZOLE, TRIAZOLE, OR TETRAZOLE Itaru Todoriki, Director of Agency of Industrial Science and Technology (JP) 1987-05-05 US claimed
US-20260035749-A1 METHODS AND COMPOSITIONS FOR PREDICTING AND/OR MONITORING CARDIOVASCULAR DISEASE AND TREATMENTS THEREFOR CARDIO DIAGNOSTICS INC (US) 2026-02-05 US disclosed
US-12297221-B2 Functionalization and purification of molecules by reversible group exchange ILLUMINA, INC. (US) 2025-05-13 US disclosed
US-20240384262-A1 LINKING SEQUENCE READS USING PAIRED CODE TAGS ILLUMINA, INC. 2024-11-21 US disclosed
US-20240360513-A1 COMPOSITIONS AND METHODS FOR DETECTING PREDISPOSITION TO CARDIOVASCULAR DISEASE UNIV IOWA RES FOUND (US) 2024-10-31 US disclosed
US-20240327916-A1 METHODS AND COMPOSITIONS FOR PREDICTING AND/OR MONITORING CARDIOVASCULAR DISEASE AND INTERVENTIONS THEREFOR Cardio Diagnostics, Inc. 2024-10-03 US disclosed
US-12043869-B2 Compositions and methods for detecting predisposition to cardiovascular disease UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2024-07-23 US disclosed
US-11993772-B2 Linking sequence reads using paired code tags ILLUMINA, INC. (US) 2024-05-28 US disclosed
US-4275149-A IMMUNOASSAY SYVA COMPANY (US) 1981-06-23 US disclosed
US-4272506-A BINDING A LABELED MEMBER OF A SPECIFIC BINDING PAIR TO A MERCAPTO-ACTIVATED SUPPORT THROUGH CLEAVABLE DISULFIDE LINKAGES; IMMUNOASSAY; ACCURACY SYVA COMPANY (US) 1981-06-09 US disclosed
US-4256834-A REPRESSING THE SIGNALS PRODUCED BY UNBOUND LABELS; SENSITIVITY SYVA COMPANY (US) 1981-03-17 US disclosed
EP-0022768-A1 MACROMOLECULAR ENVIRONMENT CONTROL IN SPECIFIC RECEPTOR ASSAYS. SYVA CO (US) 1981-01-28 EP disclosed
EP-0017908-A1 A method for determining the presence in a sample of an analyte and a kit for use in this method SYVA COMPANY (US) 1980-10-29 EP disclosed
EP-0022768-A4 MACROMOLECULAR ENVIRONMENT CONTROL IN SPECIFIC RECEPTOR ASSAYS. SYVA CO (US) 1980-08-18 EP disclosed
WO-1979000882-A1 MACROMOLECULAR ENVIRONMENT CONTROL IN SPECIFIC RECEPTOR ASSAYS SYVA CO (US) 1979-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035749-A1 METHODS AND COMPOSITIONS FOR PREDICTING AND/OR MONITORING CARDIOVASCULAR DISEASE AND TREATMENTS THEREFOR DNMT3A, MECP2, DNMT3L HTT 1564/4885HSD17B10 1383/4885ALOX15 3303/4885
US-12297221-B2 Functionalization and purification of molecules by reversible group exchange PHAX, ALKBH1, JMJD6 HTT 1045/4885HSD17B10 4845/4885ALOX15 4830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.